Manufacturer
GlaxoSmithKline
Contents
Fluticasone furoate 100 mcg, vilanterol trifenatate 25 mcg, predispensed (delivered dose of fluticasone furoate 92 mcg, vilanterol trifenatate 22 mcg)
Indication
Regular treatment of asthma in adult & adolescent ≥12 yr & not adequately controlled w/ inhaled corticosteroid & 'as needed' inhaled short-acting β2-agonist.
Symptomatic treatment of adult w/ COPD w/ FEV1 <70% predicted normal w/ an exacerbation history despite regular bronchodilator therapy.
Instruction
sthma Adult & adolescent ≥12 yr 1 inhalation of 100/25 mcg once daily, may be increased up to max 200/25 mcg. COPD 1 inhalation of 100/25 mcg once daily.
Drug interaction
Weakened or antagonized effect by β-blockers. Increased systemic exposure w/ CYP3A4 inhibitors eg, ketoconazole, ritonavir. Potentiated adverse reactions w/ other sympathomimetic drugs.
Malaysia
